drTarget portfolio target-disease associations for metabolic/endocrine disorders

OpenTargets offers > 50k target-disease associations from PChem targets suitable for virtual screening based in OpenTargets scores for metabolic/endocrine disorders. See here the best scored pairs.

Target-disease associations for metabolic/endocrine disorders.

Check best scored target-disease associations in table:

PubChemAssay	program	diseaseName	assayType	testedComopunds	activeCompounds	weightedScore	weightedEvidence
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	metabolic syndrome	targetBased	99314	335	0.614697417851648	113
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	metabolic syndrome	targetBased	196176	782	0.614697417851648	113
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	metabolic syndrome	targetBased	99314	390	0.614697417851648	113
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	metabolic syndrome	targetBased	196177	811	0.614697417851648	113
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	metabolic syndrome	targetBased	196176	670	0.614697417851648	113
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	metabolic syndrome	targetBased	196177	519	0.614697417851648	113
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	metabolic syndrome	targetBased	335531	328	0.513066064153847	6
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	pancreatitis	targetBased	343786	1253	0.554613148487925	169
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	pancreatitis	targetBased	296501	2737	0.554613148487925	169
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	diabetes mellitus	targetBased	305610	3878	0.501787244287448	334
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	diabetes mellitus	targetBased	305610	1082	0.501787244287448	334
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	diabetic nephropathy	targetBased	394050	3624	0.567904792936959	90
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	diabetic nephropathy	targetBased	405130	6428	0.555656269282092	300
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	diabetic nephropathy	targetBased	373462	23	0.555656269282092	300
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	diabetic nephropathy	targetBased	405130	6428	0.555656269282092	300
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	chronic pancreatitis	targetBased	343786	1253	0.720305011735222	173
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	chronic pancreatitis	targetBased	296501	2737	0.720305011735222	173
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	diabetes mellitus	targetBased	394050	3624	0.529105742384322	476
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	diabetes mellitus	targetBased	405130	6428	0.746078951984027	6203
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	diabetes mellitus	targetBased	373462	23	0.746078951984027	6203
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	diabetes mellitus	targetBased	405130	6428	0.746078951984027	6203
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	diabetes mellitus	targetBased	99314	335	0.832249916636913	3050
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	diabetes mellitus	targetBased	196176	782	0.832249916636913	3050
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	diabetes mellitus	targetBased	99314	390	0.832249916636913	3050
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	diabetes mellitus	targetBased	196177	811	0.832249916636913	3050
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	diabetes mellitus	targetBased	196176	670	0.832249916636913	3050
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	diabetes mellitus	targetBased	196177	519	0.832249916636913	3050
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	diabetes mellitus	targetBased	335531	328	0.6503387957345	50
qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease	GAA	diabetes mellitus	targetBased	199169	715	0.55166609042028	16
qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen	GAA_inhibitors	diabetes mellitus	targetBased	302297	1165	0.55166609042028	16
Thrombin 1536 HTS	F2_modulation	diabetes mellitus	targetBased	217233	557	0.511277238254476	101
Primary screen for compounds that activate Insulin promoter activity in TRM-6 cells	INS	diabetes mellitus	targetBased	128695	1039	0.682345221976707	3901
Primary screen for compounds that inhibit Insulin promoter activity in TRM-6 cells	INS	diabetes mellitus	targetBased	127961	1153	0.682345221976707	3901
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	metabolic disease	targetBased	99314	335	0.650932856407589	2914
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	metabolic disease	targetBased	196176	782	0.650932856407589	2914
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	metabolic disease	targetBased	99314	390	0.650932856407589	2914
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	metabolic disease	targetBased	196177	811	0.650932856407589	2914
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	metabolic disease	targetBased	196176	670	0.650932856407589	2914
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	metabolic disease	targetBased	196177	519	0.650932856407589	2914
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	portal hypertension	targetBased	339297	1446	0.579427222756886	14
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	obesity	targetBased	290355	265	0.620061063972936	23
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	obesity	targetBased	86095	1442	0.558027801578465	27
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	obesity	targetBased	86095	1151	0.558027801578465	27
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	obesity	targetBased	394050	3624	0.61655642640449	21
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	obesity	targetBased	335239	991	0.638477857428487	43
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	obesity	targetBased	335239	695	0.638477857428487	43
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	obesity	targetBased	405130	6428	0.665388121938735	202
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	obesity	targetBased	373462	23	0.665388121938735	202
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	obesity	targetBased	405130	6428	0.665388121938735	202
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	obesity	targetBased	99314	335	0.693615894867754	71
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	obesity	targetBased	196176	782	0.693615894867754	71
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	obesity	targetBased	99314	390	0.693615894867754	71
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	obesity	targetBased	196177	811	0.693615894867754	71
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	obesity	targetBased	196176	670	0.693615894867754	71
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	obesity	targetBased	196177	519	0.693615894867754	71
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	obesity	targetBased	108286	1415	0.658323474596516	83
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	obesity	targetBased	356160	3470	0.891868554414912	272
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	obesity	targetBased	356160	1703	0.891868554414912	272
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	obesity	targetBased	339297	1446	0.552014995286952	13
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	obesity	targetBased	324747	1043	0.560691974339547	9
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	obesity	targetBased	316642	617	0.5193543582675	9
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	obesity	targetBased	343468	734	0.577168330395272	6
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	morbid obesity	targetBased	335239	991	0.612786737888709	18
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	morbid obesity	targetBased	335239	695	0.612786737888709	18
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	morbid obesity	targetBased	405130	6428	0.528103011465632	23
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	morbid obesity	targetBased	373462	23	0.528103011465632	23
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	morbid obesity	targetBased	405130	6428	0.528103011465632	23
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	morbid obesity	targetBased	316642	617	0.555158533283897	8
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	liver disease	targetBased	99314	335	0.685650937463137	671
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	liver disease	targetBased	196176	782	0.685650937463137	671
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	liver disease	targetBased	99314	390	0.685650937463137	671
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	liver disease	targetBased	196177	811	0.685650937463137	671
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	liver disease	targetBased	196176	670	0.685650937463137	671
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	liver disease	targetBased	196177	519	0.685650937463137	671
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	abnormal glucose tolerance	targetBased	99314	335	0.57280694202758	8
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	abnormal glucose tolerance	targetBased	196176	782	0.57280694202758	8
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	abnormal glucose tolerance	targetBased	99314	390	0.57280694202758	8
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	abnormal glucose tolerance	targetBased	196177	811	0.57280694202758	8
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	abnormal glucose tolerance	targetBased	196176	670	0.57280694202758	8
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	abnormal glucose tolerance	targetBased	196177	519	0.57280694202758	8
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	non-alcoholic fatty liver disease	targetBased	405130	6428	0.597702476941513	707
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	non-alcoholic fatty liver disease	targetBased	373462	23	0.597702476941513	707
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	non-alcoholic fatty liver disease	targetBased	405130	6428	0.597702476941513	707
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	non-alcoholic fatty liver disease	targetBased	99314	335	0.67440205565891	877
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	non-alcoholic fatty liver disease	targetBased	196176	782	0.67440205565891	877
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	non-alcoholic fatty liver disease	targetBased	99314	390	0.67440205565891	877
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	non-alcoholic fatty liver disease	targetBased	196177	811	0.67440205565891	877
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	non-alcoholic fatty liver disease	targetBased	196176	670	0.67440205565891	877
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	non-alcoholic fatty liver disease	targetBased	196177	519	0.67440205565891	877
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	Cushing syndrome	targetBased	334825	423	0.622867247821216	68
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	Cushing syndrome	targetBased	337446	1356	0.622867247821216	68
USP8 deubiquitinase inhibition: Primary qHTS	USP8	Cushing syndrome	targetBased	47480	2010	0.600698602908734	10
Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	Graves disease	targetBased	329153	670	0.575702894356837	2048
Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	Graves disease	targetBased	329153	670	0.575702894356837	2048
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor	TSHR	Graves disease	targetBased	72026	352	0.575702894356837	2048
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293	TSHR	Graves disease	targetBased	72026	1794	0.575702894356837	2048
Primary Cell-based High Throughput Screening assay for activators of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	body mass index	pathwayBased	64908	979	0.529527129428927	12
Primary Cell-based High Throughput Screening assay for inhibitors of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	body mass index	pathwayBased	64908	278	0.529527129428927	12
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	body mass index	targetBased	99314	335	0.517791092042884	17
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	body mass index	targetBased	196176	782	0.517791092042884	17
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	body mass index	targetBased	99314	390	0.517791092042884	17
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	body mass index	targetBased	196177	811	0.517791092042884	17
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	body mass index	targetBased	196176	670	0.517791092042884	17
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	body mass index	targetBased	196177	519	0.517791092042884	17
qHTS Assay for NPC1 Promoter Activators	NPC1	body mass index	pathwayBased	320682	7575	0.500783917608923	23
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	body mass index	targetBased	356160	3470	0.793103015324844	185
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	body mass index	targetBased	356160	1703	0.793103015324844	185
SMM ID4 Measured in Biochemical System Using Small Molecule MicroArray - 2128-01_Other_SinglePoint_HTS_Activity	ID4	body fat distribution	targetBased	31324	362	0.502294312755366	6
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	body weights and measures	targetBased	356160	3470	0.694882527663013	216
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	body weights and measures	targetBased	356160	1703	0.694882527663013	216
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	body weight	targetBased	356160	3470	0.779946115907984	80
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	body weight	targetBased	356160	1703	0.779946115907984	80
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	gestational diabetes	targetBased	394050	3624	0.512465339236712	62
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	gestational diabetes	targetBased	405130	6428	0.573876632832523	32
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	gestational diabetes	targetBased	373462	23	0.573876632832523	32
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	gestational diabetes	targetBased	405130	6428	0.573876632832523	32
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity	SCARB1	triglyceride measurement	targetBased	319204	3065	0.515570905781065	10
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity	SCARB1	triglyceride measurement	targetBased	316970	306	0.515570905781065	10
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	triglyceride measurement	targetBased	99314	335	0.515247998154276	14
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	triglyceride measurement	targetBased	196176	782	0.515247998154276	14
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	triglyceride measurement	targetBased	99314	390	0.515247998154276	14
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	triglyceride measurement	targetBased	196177	811	0.515247998154276	14
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	triglyceride measurement	targetBased	196176	670	0.515247998154276	14
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	triglyceride measurement	targetBased	196177	519	0.515247998154276	14
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	triglyceride measurement	targetBased	276265	806	0.511763821304796	8
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity	SCARB1	low density lipoprotein cholesterol measurement	targetBased	319204	3065	0.507078142237239	11
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity	SCARB1	low density lipoprotein cholesterol measurement	targetBased	316970	306	0.507078142237239	11
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity	SCARB1	high density lipoprotein cholesterol measurement	targetBased	319204	3065	0.774346264551129	83
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity	SCARB1	high density lipoprotein cholesterol measurement	targetBased	316970	306	0.774346264551129	83
uHTS identification of modulators of interaction between CendR and NRP-1 using Fluorescence Polarization assay	NRP1	high density lipoprotein cholesterol measurement	targetBased	363840	3086	0.513255797802339	14
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	high density lipoprotein cholesterol measurement	targetBased	99314	335	0.709062972457657	42
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	high density lipoprotein cholesterol measurement	targetBased	196176	782	0.709062972457657	42
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	high density lipoprotein cholesterol measurement	targetBased	99314	390	0.709062972457657	42
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	high density lipoprotein cholesterol measurement	targetBased	196177	811	0.709062972457657	42
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	high density lipoprotein cholesterol measurement	targetBased	196176	670	0.709062972457657	42
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	high density lipoprotein cholesterol measurement	targetBased	196177	519	0.709062972457657	42
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	high density lipoprotein cholesterol measurement	targetBased	356160	3470	0.517829028574134	24
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	high density lipoprotein cholesterol measurement	targetBased	356160	1703	0.517829028574134	24
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity	SCARB1	total cholesterol measurement	targetBased	319204	3065	0.720081380330332	28
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity	SCARB1	total cholesterol measurement	targetBased	316970	306	0.720081380330332	28
Primary cell-based high throughput screening assay to measure STAT1 activation	STAT1 activation	hypothyroidism	pathwayBased	195980	5134	0.506525369873782	28
Primary cell-based high throughput screening assay to measure STAT1 inhibition	STAT1	hypothyroidism	targetBased	195980	695	0.506525369873782	28
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	hypothyroidism	targetBased	276265	806	0.676224852086246	502
Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	hypothyroidism	targetBased	329153	670	0.852391824258962	546
Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	hypothyroidism	targetBased	329153	670	0.852391824258962	546
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor	TSHR	hypothyroidism	targetBased	72026	352	0.852391824258962	546
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293	TSHR	hypothyroidism	targetBased	72026	1794	0.852391824258962	546
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	lean body mass	targetBased	86095	1442	0.605276599282585	33
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	lean body mass	targetBased	86095	1151	0.605276599282585	33
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	lean body mass	targetBased	335239	991	0.521145657342475	17
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	lean body mass	targetBased	335239	695	0.521145657342475	17
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	lean body mass	targetBased	305610	2592	0.50328478437926	17
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	lean body mass	targetBased	356160	3470	0.797055288021613	210
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	lean body mass	targetBased	356160	1703	0.797055288021613	210
HTS of Smad transcription factor inhibitors	SMAD3	lean body mass	targetBased	88033	251	0.522966736589418	12
SMM ID4 Measured in Biochemical System Using Small Molecule MicroArray - 2128-01_Other_SinglePoint_HTS_Activity	ID4	lean body mass	targetBased	31324	362	0.557680215912674	29
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity	SCARB1	lipoprotein measurement	targetBased	319204	3065	0.737641092943203	90
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity	SCARB1	lipoprotein measurement	targetBased	316970	306	0.737641092943203	90
HTS identification of compounds activating phosphomannose isomerase (PMI) via a fluorescence intensity assay using a near- saturating concentration of mannose 6-phosphat	MPI	congenital disorder of glycosylation type I	targetBased	194152	656	0.582877315384715	260
HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay using a high concentration of mannose 6-phosphate	MPI	congenital disorder of glycosylation type I	targetBased	194152	1288	0.582877315384715	260
HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay.	MPI	congenital disorder of glycosylation type I	targetBased	194152	814	0.582877315384715	260
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	fat body mass	targetBased	356160	3470	0.792334309492539	188
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	fat body mass	targetBased	356160	1703	0.792334309492539	188
SMM ID4 Measured in Biochemical System Using Small Molecule MicroArray - 2128-01_Other_SinglePoint_HTS_Activity	ID4	fat body mass	targetBased	31324	362	0.521144086906474	11
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	parathyroid disease	targetBased	394050	3624	0.612533808842894	202
qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide	Menin-MLL_inhibitors	parathyroid disease	targetBased	263421	615	0.672577744708436	1855
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	hyperprolactinemia	targetBased	359518	300	0.622566399114305	15
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	hyperprolactinemia	targetBased	335652	1779	0.622566399114305	15
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	hyperprolactinemia	targetBased	362274	1056	0.622566399114305	15
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	hyperprolactinemia	targetBased	336308	6862	0.622566399114305	15
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	hyperprolactinemia	targetBased	357537	806	0.622566399114305	15
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	hyperprolactinemia	targetBased	339887	1178	0.622566399114305	15
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	hyperprolactinemia	targetBased	407539	2380	0.605697325591456	11
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	hyperprolactinemia	targetBased	364051	9106	0.605697325591456	11
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	hyperprolactinemia	targetBased	407539	2380	0.605697325591456	11
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	body fat percentage	targetBased	99314	335	0.576341088252982	45
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	body fat percentage	targetBased	196176	782	0.576341088252982	45
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	body fat percentage	targetBased	99314	390	0.576341088252982	45
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	body fat percentage	targetBased	196177	811	0.576341088252982	45
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	body fat percentage	targetBased	196176	670	0.576341088252982	45
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	body fat percentage	targetBased	196177	519	0.576341088252982	45
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	body fat percentage	targetBased	356160	3470	0.790829523756632	128
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	body fat percentage	targetBased	356160	1703	0.790829523756632	128
Cell-based high throughput primary assay to identify activators of GPR151	GPR151	body fat percentage	targetBased	642701	6746	0.510129293451637	14
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	base metabolic rate measurement	targetBased	356160	3470	0.746509529530886	33
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	base metabolic rate measurement	targetBased	356160	1703	0.746509529530886	33
qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide	Menin-MLL_inhibitors	hyperparathyroidism	targetBased	263421	615	0.832240869271689	1881
Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	hyperthyroidism	targetBased	329153	670	0.603756541413275	1906
Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	hyperthyroidism	targetBased	329153	670	0.603756541413275	1906
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor	TSHR	hyperthyroidism	targetBased	72026	352	0.603756541413275	1906
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293	TSHR	hyperthyroidism	targetBased	72026	1794	0.603756541413275	1906
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	hyperthyroidism	targetBased	339297	1446	0.523521299969412	12
Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	Thyrotoxicosis	targetBased	329153	670	0.517506253480117	315
Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	Thyrotoxicosis	targetBased	329153	670	0.517506253480117	315
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor	TSHR	Thyrotoxicosis	targetBased	72026	352	0.517506253480117	315
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293	TSHR	Thyrotoxicosis	targetBased	72026	1794	0.517506253480117	315
qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide	Menin-MLL_inhibitors	primary hyperparathyroidism	targetBased	263421	615	0.731336275407759	1712
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	hypoparathyroidism	targetBased	394050	3624	0.641977609633434	58
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	hypoparathyroidism	targetBased	405685	308	0.61948357909798	44
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	whole body water mass	targetBased	356160	3470	0.724805104839169	30
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	whole body water mass	targetBased	356160	1703	0.724805104839169	30
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity	SCARB1	cholesteryl ester measurement	targetBased	319204	3065	0.605296400781166	14
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity	SCARB1	cholesteryl ester measurement	targetBased	316970	306	0.605296400781166	14
uHTS identification of TNAP inhibitors in the absence of phosphate acceptor performed in luminescent assay	ALPL_inhibitors	infantile hypophosphatasia	targetBased	195560	517	0.90622530582871	371
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity	SCARB1	concentration of large HDL particles measurement	targetBased	319204	3065	0.589321137126282	11
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity	SCARB1	concentration of large HDL particles measurement	targetBased	316970	306	0.589321137126282	11
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	lipodystrophy	targetBased	99314	335	0.538756514793434	170
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	lipodystrophy	targetBased	196176	782	0.538756514793434	170
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	lipodystrophy	targetBased	99314	390	0.538756514793434	170
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	lipodystrophy	targetBased	196177	811	0.538756514793434	170
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	lipodystrophy	targetBased	196176	670	0.538756514793434	170
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	lipodystrophy	targetBased	196177	519	0.538756514793434	170
Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	thyroid disease	targetBased	329153	670	0.834278902759498	1999
Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	thyroid disease	targetBased	329153	670	0.834278902759498	1999
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor	TSHR	thyroid disease	targetBased	72026	352	0.834278902759498	1999
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293	TSHR	thyroid disease	targetBased	72026	1794	0.834278902759498	1999
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	myxedema	targetBased	276265	806	0.577168330395272	6
Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	myxedema	targetBased	329153	670	0.647247201046324	83
Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	myxedema	targetBased	329153	670	0.647247201046324	83
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor	TSHR	myxedema	targetBased	72026	352	0.647247201046324	83
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293	TSHR	myxedema	targetBased	72026	1794	0.647247201046324	83
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	nodular goiter	targetBased	276265	806	0.514169279031916	7
USP8 deubiquitinase inhibition: Primary qHTS	USP8	pituitary-dependent Cushing's disease	targetBased	47480	2010	0.551867769967705	8
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	prediabetes syndrome	targetBased	405130	6428	0.596101338955186	71
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	prediabetes syndrome	targetBased	373462	23	0.596101338955186	71
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	prediabetes syndrome	targetBased	405130	6428	0.596101338955186	71
qHTS Assay for NPC1 Promoter Activators	NPC1	Niemann-Pick disease	pathwayBased	320682	7575	0.810720962981773	1356
uHTS identification of small molecule modulators of NR3A	GRIN3A	postencephalitic Parkinson disease	targetBased	339772	8480	0.638992421523723	21
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	secondary hyperparathyroidism	targetBased	394050	3624	0.6628175930313	274
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	secondary Parkinson disease	pathwayBased	376029	3978	0.567451434636309	6
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	secondary Parkinson disease	targetBased	322361	619	0.585513080048089	14
uHTS identification of small molecule modulators of NR3A	GRIN3A	secondary Parkinson disease	targetBased	339772	8480	0.643570744246353	28
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	non-alcoholic steatohepatitis	targetBased	99314	335	0.582785079482869	375
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	non-alcoholic steatohepatitis	targetBased	196176	782	0.582785079482869	375
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	non-alcoholic steatohepatitis	targetBased	99314	390	0.582785079482869	375
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	non-alcoholic steatohepatitis	targetBased	196177	811	0.582785079482869	375
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	non-alcoholic steatohepatitis	targetBased	196176	670	0.582785079482869	375
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	non-alcoholic steatohepatitis	targetBased	196177	519	0.582785079482869	375
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	Central diabetes insipidus	targetBased	324747	813	0.60466648961276	9
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	Hyperglycemia	targetBased	405130	6428	0.516596040424956	758
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	Hyperglycemia	targetBased	373462	23	0.516596040424956	758
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	Hyperglycemia	targetBased	405130	6428	0.516596040424956	758
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	Hypercholesterolemia	targetBased	335531	328	0.575286284252107	9
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	thyroid hormone resistance syndrome	targetBased	276265	806	0.74824198378622	236
qHTS assay for inhibitors of human lactate dehydrogenase	lactateDehydrogenaseInhibitors	disorder of glycogen metabolism	targetBased	476056	732	0.650586578528587	90
qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease	GAA	disorder of glycogen metabolism	targetBased	199169	715	0.692888266555033	1495
qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen	GAA_inhibitors	disorder of glycogen metabolism	targetBased	302297	1165	0.692888266555033	1495
qHTS assay for re-activators of p53 using a Luc reporter	TP53	lysosomal storage disease	pathwayBased	321427	201	0.510748835743924	23
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	lysosomal storage disease	targetBased	54509	528	0.510748835743924	23
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	lysosomal storage disease	targetBased	54513	338	0.510748835743924	23
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	lysosomal storage disease	targetBased	125394	1890	0.510748835743924	23
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	lysosomal storage disease	targetBased	124022	1156	0.510748835743924	23
Fluorescence polarization assay for PLK1 inhibitors	PLK1	lysosomal storage disease	targetBased	97099	518	0.577168330395272	6
qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen	PLK1	lysosomal storage disease	targetBased	364065	10181	0.577168330395272	6
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	lysosomal storage disease	pathwayBased	43989	342	0.511744604694731	47
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	type 1 diabetes mellitus	targetBased	394050	3624	0.623714942338902	286
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	type 1 diabetes mellitus	targetBased	405130	6428	0.667118677384461	374
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	type 1 diabetes mellitus	targetBased	373462	23	0.667118677384461	374
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	type 1 diabetes mellitus	targetBased	405130	6428	0.667118677384461	374
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	type 1 diabetes mellitus	targetBased	99314	335	0.530795116220742	83
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	type 1 diabetes mellitus	targetBased	196176	782	0.530795116220742	83
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	type 1 diabetes mellitus	targetBased	99314	390	0.530795116220742	83
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	type 1 diabetes mellitus	targetBased	196177	811	0.530795116220742	83
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	type 1 diabetes mellitus	targetBased	196176	670	0.530795116220742	83
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	type 1 diabetes mellitus	targetBased	196177	519	0.530795116220742	83
Primary screen for compounds that activate Insulin promoter activity in TRM-6 cells	INS	type 1 diabetes mellitus	targetBased	128695	1039	0.756980358905614	1970
Primary screen for compounds that inhibit Insulin promoter activity in TRM-6 cells	INS	type 1 diabetes mellitus	targetBased	127961	1153	0.756980358905614	1970
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	type 2 diabetes mellitus	targetBased	305610	3878	0.66637441362342	573
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	type 2 diabetes mellitus	targetBased	305610	1082	0.66637441362342	573
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	type 2 diabetes mellitus	targetBased	394050	3624	0.630637978861556	347
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	type 2 diabetes mellitus	targetBased	405130	6428	0.822214179786226	8610
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	type 2 diabetes mellitus	targetBased	373462	23	0.822214179786226	8610
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	type 2 diabetes mellitus	targetBased	405130	6428	0.822214179786226	8610
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	type 2 diabetes mellitus	targetBased	99314	335	0.920445028915377	3693
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	type 2 diabetes mellitus	targetBased	196176	782	0.920445028915377	3693
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	type 2 diabetes mellitus	targetBased	99314	390	0.920445028915377	3693
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	type 2 diabetes mellitus	targetBased	196177	811	0.920445028915377	3693
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	type 2 diabetes mellitus	targetBased	196176	670	0.920445028915377	3693
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	type 2 diabetes mellitus	targetBased	196177	519	0.920445028915377	3693
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	type 2 diabetes mellitus	targetBased	359518	300	0.639626764279892	80
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	type 2 diabetes mellitus	targetBased	335652	1779	0.639626764279892	80
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	type 2 diabetes mellitus	targetBased	362274	1056	0.639626764279892	80
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	type 2 diabetes mellitus	targetBased	336308	6862	0.639626764279892	80
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	type 2 diabetes mellitus	targetBased	357537	806	0.639626764279892	80
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	type 2 diabetes mellitus	targetBased	339887	1178	0.639626764279892	80
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	type 2 diabetes mellitus	targetBased	407539	2380	0.619586482443362	21
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	type 2 diabetes mellitus	targetBased	364051	9106	0.619586482443362	21
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	type 2 diabetes mellitus	targetBased	407539	2380	0.619586482443362	21
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	type 2 diabetes mellitus	targetBased	335531	328	0.57586675548928	30
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	type 2 diabetes mellitus	targetBased	356160	3470	0.55611341627735	228
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	type 2 diabetes mellitus	targetBased	356160	1703	0.55611341627735	228
qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease	GAA	type 2 diabetes mellitus	targetBased	199169	715	0.633159771804883	32
qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen	GAA_inhibitors	type 2 diabetes mellitus	targetBased	302297	1165	0.633159771804883	32
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	familial partial lipodystrophy, Dunnigan type	targetBased	99314	335	0.61433213627937	87
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	familial partial lipodystrophy, Dunnigan type	targetBased	196176	782	0.61433213627937	87
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	familial partial lipodystrophy, Dunnigan type	targetBased	99314	390	0.61433213627937	87
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	familial partial lipodystrophy, Dunnigan type	targetBased	196177	811	0.61433213627937	87
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	familial partial lipodystrophy, Dunnigan type	targetBased	196176	670	0.61433213627937	87
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	familial partial lipodystrophy, Dunnigan type	targetBased	196177	519	0.61433213627937	87
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	selective pituitary resistance to thyroid hormone	targetBased	276265	806	0.819781482042683	48
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the prolyl oligopeptidase-like enzyme (PREPL)	PREPL	cystinuria	targetBased	324747	2221	0.610967494573669	95
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	hereditary chronic pancreatitis	targetBased	343786	1253	0.777489202209142	461
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	hereditary chronic pancreatitis	targetBased	296501	2737	0.777489202209142	461
qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization	MAPT	late-onset Parkinson disease	pathwayBased	271402	1048	0.554854250374523	6
qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding	MAPT	late-onset Parkinson disease	pathwayBased	267412	5703	0.554854250374523	6
qHTS Assay for Tau Filament Binding	MAPT	late-onset Parkinson disease	targetBased	69668	1391	0.554854250374523	6
Glucocerebrosidase	GBA1	Gaucher disease-ophthalmoplegia-cardiovascular calcification syndrome	targetBased	48118	549	0.779415318502638	122
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	generalized resistance to thyroid hormone	targetBased	276265	806	0.770774380396017	44
uHTS Identification of Diaphorase Inhibitors and Chemcical Oxidizers: Counter Screen for Diaphorase-based Primary Assays	DiaphoraseInhibitors	pyruvate dehydrogenase E3 deficiency	targetBased	194152	1342	0.909058118974501	882
uHTS Identification of Diaphorase Inhibitors and Chemcical Oxidizers: Counter Screen for Diaphorase-based Primary Assays	DiaphoraseInhibitors	maple syrup urine disease	targetBased	194152	1342	0.726575680343748	1132
uHTS Identification of Diaphorase Inhibitors and Chemcical Oxidizers: Counter Screen for Diaphorase-based Primary Assays	DiaphoraseInhibitors	Leigh syndrome	targetBased	194152	1342	0.702759335081669	123
qHTS for Agonists of the Human Mucolipin Transient Receptor Potential 1 (TRPML1)	MCOLN1	mucolipidosis type IV	targetBased	400814	482	0.926582257823166	1539
Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	hypothyroidism due to TSH receptor mutations	targetBased	329153	670	0.876175090766287	206
Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	hypothyroidism due to TSH receptor mutations	targetBased	329153	670	0.876175090766287	206
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor	TSHR	hypothyroidism due to TSH receptor mutations	targetBased	72026	352	0.876175090766287	206
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293	TSHR	hypothyroidism due to TSH receptor mutations	targetBased	72026	1794	0.876175090766287	206
uHTS identification of small molecule inhibitors of Artemis endonuclease activity via a fluorescence intensity assay	artemis_inhibitors	severe combined immunodeficiency due to DCLRE1C deficiency	targetBased	30104	235	0.890628296247178	1470
qHTS for Inhibitors of Polymerase Eta	POLH	xeroderma pigmentosum variant type	targetBased	388717	4730	0.860919268933285	369
HTS identification of compounds activating phosphomannose isomerase (PMI) via a fluorescence intensity assay using a near- saturating concentration of mannose 6-phosphat	MPI	MPI-congenital disorder of glycosylation	targetBased	194152	656	0.92306803154231	773
HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay using a high concentration of mannose 6-phosphate	MPI	MPI-congenital disorder of glycosylation	targetBased	194152	1288	0.92306803154231	773
HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay.	MPI	MPI-congenital disorder of glycosylation	targetBased	194152	814	0.92306803154231	773
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	pseudohypoparathyroidism type 1B	targetBased	334825	423	0.884574613045788	245
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	pseudohypoparathyroidism type 1B	targetBased	337446	1356	0.884574613045788	245
Glucocerebrosidase	GBA1	Gaucher disease perinatal lethal	targetBased	48118	549	0.87178890644602	119
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the prolyl oligopeptidase-like enzyme (PREPL)	PREPL	hypotonia-cystinuria syndrome	targetBased	324747	2221	0.603812914945978	23
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG-related familial partial lipodystrophy	targetBased	99314	335	0.853828081057315	135
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG-related familial partial lipodystrophy	targetBased	196176	782	0.853828081057315	135
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG-related familial partial lipodystrophy	targetBased	99314	390	0.853828081057315	135
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG-related familial partial lipodystrophy	targetBased	196177	811	0.853828081057315	135
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG-related familial partial lipodystrophy	targetBased	196176	670	0.853828081057315	135
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG-related familial partial lipodystrophy	targetBased	196177	519	0.853828081057315	135
Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	familial hyperthyroidism due to mutations in TSH receptor	targetBased	329153	670	0.78816112707411	209
Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	familial hyperthyroidism due to mutations in TSH receptor	targetBased	329153	670	0.78816112707411	209
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor	TSHR	familial hyperthyroidism due to mutations in TSH receptor	targetBased	72026	352	0.78816112707411	209
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293	TSHR	familial hyperthyroidism due to mutations in TSH receptor	targetBased	72026	1794	0.78816112707411	209
qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1)	TDP1	spinocerebellar ataxia, autosomal recessive, with axonal neuropathy 1	targetBased	344442	978	0.615241893026113	162
qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT	TDP1	spinocerebellar ataxia, autosomal recessive, with axonal neuropathy 1	targetBased	416824	63248	0.615241893026113	162
qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT	TDP1	spinocerebellar ataxia, autosomal recessive, with axonal neuropathy 1	targetBased	416856	49238	0.615241893026113	162
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	aldosterone-producing adenoma with seizures and neurological abnormalities	targetBased	335531	328	0.824148217889939	128
HTS identification of compounds activating phosphomannose isomerase (PMI) via a fluorescence intensity assay using a near- saturating concentration of mannose 6-phosphat	MPI	congenital disorder of glycosylation	targetBased	194152	656	0.735305299331021	997
HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay using a high concentration of mannose 6-phosphate	MPI	congenital disorder of glycosylation	targetBased	194152	1288	0.735305299331021	997
HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay.	MPI	congenital disorder of glycosylation	targetBased	194152	814	0.735305299331021	997
Primary screen for compounds that activate Insulin promoter activity in TRM-6 cells	INS	neonatal diabetes mellitus	targetBased	128695	1039	0.608360646017274	151
Primary screen for compounds that inhibit Insulin promoter activity in TRM-6 cells	INS	neonatal diabetes mellitus	targetBased	127961	1153	0.608360646017274	151
uHTS identification of TNAP inhibitors in the absence of phosphate acceptor performed in luminescent assay	ALPL_inhibitors	odontohypophosphatasia	targetBased	195560	517	0.741759323098823	20
qHTS Assay for Activators of ClpP	Bacillus subtilis (strain 168)	Perrault syndrome	targetBased	338378	6439	0.851666345145291	107
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	hereditary sensory and autonomic neuropathy type 1	targetBased	359244	2975	0.678383562696946	2457
Inhibitors of Cav3 T-type Calcium Channels: Primary Screen	CACNA1H_inhibitors	familial hyperaldosteronism	targetBased	104728	4230	0.579874415386324	5432
Glucocerebrosidase	GBA1	Gaucher disease	targetBased	48118	549	0.823552732111791	2711
qHTS for Agonists of the Human Mucolipin Transient Receptor Potential 1 (TRPML1)	MCOLN1	mucolipidosis	targetBased	400814	482	0.558287279679423	524
uHTS identification of TNAP inhibitors in the absence of phosphate acceptor performed in luminescent assay	ALPL_inhibitors	hypophosphatasia	targetBased	195560	517	0.896956238684656	1435
HTS for PAX8 inhibitors using PAX8 luciferase reporter gene assay in RMG-I cells Measured in Cell-Based System Using Plate Reader - 7054-01_Inhibitor_SinglePoint_HTS_Activity	PAX8	congenital hypothyroidism	targetBased	353950	4145	0.722405177821548	288
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	congenital hypothyroidism	targetBased	276265	806	0.611703580698182	39
Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	congenital hypothyroidism	targetBased	329153	670	0.645401662748241	232
Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	congenital hypothyroidism	targetBased	329153	670	0.645401662748241	232
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor	TSHR	congenital hypothyroidism	targetBased	72026	352	0.645401662748241	232
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293	TSHR	congenital hypothyroidism	targetBased	72026	1794	0.645401662748241	232
Primary screen for compounds that activate Insulin promoter activity in TRM-6 cells	INS	maturity-onset diabetes of the young	targetBased	128695	1039	0.629780097686834	56
Primary screen for compounds that inhibit Insulin promoter activity in TRM-6 cells	INS	maturity-onset diabetes of the young	targetBased	127961	1153	0.629780097686834	56
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	obesity due to melanocortin 4 receptor deficiency	targetBased	356160	3470	0.739222725453875	152
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	obesity due to melanocortin 4 receptor deficiency	targetBased	356160	1703	0.739222725453875	152
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	inherited obesity	targetBased	99314	335	0.624128943995849	13
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	inherited obesity	targetBased	196176	782	0.624128943995849	13
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	inherited obesity	targetBased	99314	390	0.624128943995849	13
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	inherited obesity	targetBased	196177	811	0.624128943995849	13
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	inherited obesity	targetBased	196176	670	0.624128943995849	13
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	inherited obesity	targetBased	196177	519	0.624128943995849	13
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	inherited obesity	targetBased	356160	3470	0.557144807777269	70
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	inherited obesity	targetBased	356160	1703	0.557144807777269	70
qHTS Assay for NPC1 Promoter Activators	NPC1	Niemann-Pick disease type C	pathwayBased	320682	7575	0.875385794852707	3870
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	retinitis pigmentosa	targetBased	326888	645	0.512584351790701	68
Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)	NR2E3	retinitis pigmentosa	targetBased	362026	1281	0.794921236355417	203
TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).	NR2E3	retinitis pigmentosa	targetBased	314998	380	0.794921236355417	203
qHTS for Inhibitors of Polymerase Eta	POLH	xeroderma pigmentosum	targetBased	388717	4730	0.633286070298763	248
HTS for PAX8 inhibitors using PAX8 luciferase reporter gene assay in RMG-I cells Measured in Cell-Based System Using Plate Reader - 7054-01_Inhibitor_SinglePoint_HTS_Activity	PAX8	thyroid hypoplasia	targetBased	353950	4145	0.509848214804856	35
Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	thyroid hypoplasia	targetBased	329153	670	0.511564109249492	41
Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	thyroid hypoplasia	targetBased	329153	670	0.511564109249492	41
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor	TSHR	thyroid hypoplasia	targetBased	72026	352	0.511564109249492	41
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293	TSHR	thyroid hypoplasia	targetBased	72026	1794	0.511564109249492	41
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	pseudohypoparathyroidism	targetBased	334825	423	0.734855055294246	573
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	pseudohypoparathyroidism	targetBased	337446	1356	0.734855055294246	573
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	hyperlipidemia	targetBased	335531	328	0.643396782824324	27
Primary screen for compounds that activate Insulin promoter activity in TRM-6 cells	INS	diabetes mellitus, permanent neonatal 4	targetBased	128695	1039	0.827937679728068	86
Primary screen for compounds that inhibit Insulin promoter activity in TRM-6 cells	INS	diabetes mellitus, permanent neonatal 4	targetBased	127961	1153	0.827937679728068	86
Primary screen for compounds that activate Insulin promoter activity in TRM-6 cells	INS	permanent neonatal diabetes mellitus	targetBased	128695	1039	0.777959509145123	63
Primary screen for compounds that inhibit Insulin promoter activity in TRM-6 cells	INS	permanent neonatal diabetes mellitus	targetBased	127961	1153	0.777959509145123	63
Dicer-mediated maturation of pre-microRNA	Dicer_inhibitors	Familial multinodular goiter	targetBased	46715	2829	0.763909243189879	84
Primary qHTS assay for inhibitors of alpha-synuclein gene (SNCA) expression	SNCA	Young adult-onset Parkinsonism	pathwayBased	140118	236	0.769243896644589	113
qHTS of alpha-syn Inhibitors	SNCA	Young adult-onset Parkinsonism	pathwayBased	368791	501	0.769243896644589	113
Glucocerebrosidase	GBA1	Gaucher disease - ophthalmoplegia - cardiovascular calcification	targetBased	48118	549	0.507250879663592	6
Glucocerebrosidase	GBA1	Gaucher disease type 2	targetBased	48118	549	0.881332474439115	207
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	Ocular albinism with congenital sensorineural deafness	targetBased	331360	2760	0.643378037527545	8
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF inhibitors	Ocular albinism with congenital sensorineural deafness	targetBased	642362	5830	0.643378037527545	8
Primary qHTS assay for inhibitors of alpha-synuclein gene (SNCA) expression	SNCA	Hereditary late-onset Parkinson disease	pathwayBased	140118	236	0.870085087181022	125
qHTS of alpha-syn Inhibitors	SNCA	Hereditary late-onset Parkinson disease	pathwayBased	368791	501	0.870085087181022	125
Glucocerebrosidase	GBA1	Hereditary late-onset Parkinson disease	targetBased	48118	549	0.624207386504889	108
qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization	MAPT	Hereditary late-onset Parkinson disease	pathwayBased	271402	1048	0.538121040106858	23
qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding	MAPT	Hereditary late-onset Parkinson disease	pathwayBased	267412	5703	0.538121040106858	23
qHTS Assay for Tau Filament Binding	MAPT	Hereditary late-onset Parkinson disease	targetBased	69668	1391	0.538121040106858	23
Primary screen for compounds that activate Insulin promoter activity in TRM-6 cells	INS	MODY	targetBased	128695	1039	0.801268492989806	168
Primary screen for compounds that inhibit Insulin promoter activity in TRM-6 cells	INS	MODY	targetBased	127961	1153	0.801268492989806	168

Some of these associations have also gone through clinical trials, as those in the graph below.

graph

Find clinical trials details in table. Use scroll bar or search funtion to select specific drugs, molecular targets or diseases.

table